Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Published: Jul 02, 2018
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. The offering was made only by means of a prospectus, copies of which may be obtained from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing firstname.lastname@example.org; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204, or by emailing email@example.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, or facsimile: 631-254-7140.
Registration statements relating to these securities has been filed with the U.S. Securities and Exchange Commission and became effective under the Securities Act of 1933, as amended, on June 27, 2018. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease.
Jackie Cossmon, IRC
Vice President of Investor Relations and Communications
Source: Tricida, Inc.